Glickman Mark A 4
4 · Esperion Therapeutics, Inc. · Filed Jan 3, 2020
Insider Transaction Report
Form 4
Glickman Mark A
Chief Commercial Officer
Transactions
- Award
Common Stock
2020-01-02+5,925→ 25,925 total - Award
Stock Option (right to buy
2020-01-02+26,625→ 26,625 totalExercise: $61.34Exp: 2030-01-02→ Common Stock (26,625 underlying)
Footnotes (1)
- [F1]The award will vest over a four (4) year period in equal quarterly installments, the first of which will be on April 2, 2020.